WHWK Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Whitehawk Therapeutics Inc (WHWK) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company has promising developments in its pipeline and positive analyst ratings, the lack of immediate catalysts, poor financial performance, and pre-market price decline suggest it is better to wait for further developments or a more favorable entry point.
The stock shows bullish moving averages (SMA_5 > SMA_20 > SMA_200) and a positive MACD histogram, indicating a potential upward trend. However, RSI is neutral at 64.755, and the pre-market price is down 1.92%, suggesting mixed momentum. Key support is at 3.51, and resistance is at 4.316.
Promising preclinical data presented at AACR 2026, showing tumor regressions and favorable tolerability for its ADC pipeline.
Ongoing Phase 1 trials and IND submission for HWK-206 in mid-
Analyst ratings from Citizens and Oppenheimer with Outperform ratings and price targets of $8 and $6, respectively.
Hedge funds are actively buying, with a 230.74% increase in buying activity over the last quarter.
Revenue dropped to zero in Q4 2025, indicating no current income generation.
Pre-market price is down 1.92%, reflecting negative sentiment.
High implied volatility (538.
and lack of significant options trading volume suggest uncertainty and limited interest in the stock.
No recent congress trading data or influential figure activity to support confidence.
In Q4 2025, revenue dropped to $0 (-100% YoY), indicating no income generation. However, net income improved to -$23.25M (+27.24% YoY), and EPS increased to -2.25 (+235.82% YoY). Gross margin improved slightly to 89.36% (+0.30% YoY), but the overall financials remain weak.
Analysts from Citizens and Oppenheimer have initiated coverage with Outperform ratings and price targets of $8 and $6, respectively. They highlight the company's promising ADC pipeline and potential for significant upside, but the timeline for clinical data and trials extends into 2026 and beyond, making it a longer-term play.
